$4.09
0.37% yesterday
NYSE, Oct 24, 10:00 pm CET
ISIN
CH0499880968
Symbol
ADCT

Adc Therapeutics SA Stock price

$4.09
+0.53 14.89% 1M
+2.73 200.74% 6M
+2.10 105.53% YTD
+1.20 41.52% 1Y
-0.46 10.11% 3Y
-22.63 84.69% 5Y
-25.56 86.21% 10Y
-25.56 86.21% 20Y
NYSE, Closing price Fri, Oct 24 2025
+0.02 0.49%
ISIN
CH0499880968
Symbol
ADCT
Industry

Key metrics

Basic
Market capitalization
$460.1m
Enterprise Value
$643.3m
Net debt
$183.2m
Cash
$264.6m
Shares outstanding
112.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.0 | 5.7
EV/Sales
8.3 | 8.0
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-62.9%
Return on Equity
77.9%
ROCE
-49.6%
ROIC
-348.3%
Debt/Equity
-2.2
Financials (TTM | estimate)
Revenue
$77.3m | $80.4m
EBITDA
$-127.2m | $-169.3m
EBIT
$-127.5m | $-141.3m
Net Income
$-169.9m | $-174.0m
Free Cash Flow
$-127.9m
Growth (TTM | estimate)
Revenue
-35.4% | 13.5%
EBITDA
51.9% | -30.9%
EBIT
52.0% | -8.1%
Net Income
54.2% | -10.2%
Free Cash Flow
12.2%
Margin (TTM | estimate)
Gross
93.4%
EBITDA
-164.6% | -210.7%
EBIT
-165.1%
Net
-220.0% | -216.4%
Free Cash Flow
-165.6%
More
EPS
$-1.5
FCF per Share
$-1.1
Short interest
5.8%
Employees
264
Rev per Employee
$270.0k
Show more

Is Adc Therapeutics SA a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.

Adc Therapeutics SA Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Adc Therapeutics SA forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Adc Therapeutics SA forecast:

Buy
92%
Hold
8%

Financial data from Adc Therapeutics SA

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
77 77
35% 35%
100%
- Direct Costs 5.12 5.12
23% 23%
7%
72 72
36% 36%
93%
- Selling and Administrative Expenses 81 81
53% 53%
105%
- Research and Development Expense 119 119
42% 42%
154%
-127 -127
52% 52%
-165%
- Depreciation and Amortization 0.36 0.36
76% 76%
0%
EBIT (Operating Income) EBIT -128 -128
52% 52%
-165%
Net Profit -170 -170
54% 54%
-220%

In millions USD.

Don't miss a Thing! We will send you all news about Adc Therapeutics SA directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adc Therapeutics SA Stock News

Neutral
PRNewsWire
12 days ago
LAUSANNE, Switzerland , Oct. 13, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $60.0 million private investment in public equity ("PIPE") financ...
Neutral
PRNewsWire
24 days ago
LAUSANNE, Switzerland , Oct. 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 162,000 of the Company's common shares to four new employees on October 1, 2025 (each, a "Grant"). The Grants were offered as ma...
Neutral
PRNewsWire
about 2 months ago
LAUSANNE, Switzerland , Sept. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 29,700 of the Company's common shares to two new employees on September 2, 2025 (each, a "Grant").
More Adc Therapeutics SA News

Company Profile

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its products include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Head office Switzerland
CEO Ameet Mallik
Employees 264
Founded 2011
Website adctherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today